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A B S T R A C T
Splenic marginal zone lymphoma (SMZL) is a distinct low grade B-cell lymphoma with an
immunophenotype similar to that of splenic marginal zone B-cells. Like the normal splenic marginal zone
B-cells, SMZLs also show variable features in somatic mutations of their rearranged immunoglobulin genes,
with ∼90% of cases harbouring somatic mutations but at remarkably variable degrees, suggesting that
SMZL may have multiple cell of origins, deriving from the heterogeneous B-cells of the splenic marginal
zone. Notably, ∼30% of SMZLs show biased usage of IGHV1-2*04, with the expressed BCR being poten-
tially polyreactive to autoantigens. Recent exome and targeted sequencing studies have identiﬁed a wide
spectrum of somatic mutations in SMZL with the recurrent mutations targeting multiple signalling path-
ways that govern the development of splenic marginal zone B-cells. These recurrent mutations occur in
KLF2 (20–42%), NOTCH2 (6.5–25%), NF-κB (CARD11 ∼7%, IKBKB ∼7%, TNFAIP3 7–13%, TRAF3 5%, BIRC3 6.3%)
and TLR (MYD88 5–13%) signalling pathways. Interestingly, the majority of SMZL with KLF2 mutation have
both 7q32 deletion and IGHV1-2 rearrangement, and these cases also have additional mutations in NOTCH2,
or TNFAIP3, or TRAF3. There is a potential oncogenic cooperation among concurrent genetic changes, for
example between the IGHV1-2 expressing BCR and KLF2 mutation in activation of the canonical NF-κB
pathway, and between KLF2 and TRAF3mutations in activation of the non-canonical NF-κB pathway. These
novel genetic ﬁndings have provided considerable insights into the pathogenesis of SMZL and will stim-
ulate the research in both normal and malignant marginal zone B-cells.
© 2015 The Author. Published by Elsevier Ltd on behalf of The Royal College of Pathologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Splenic marginal zone lymphoma (SMZL) is a distinct low grade B-cell lymphoma, accounting for <2% of lymphoid neoplasm. Clini-
cally, it is featured by splenomegaly, moderate lymphocytosis and sometimes autoimmune thrombocytopaenia or anaemia [1–3]. Histologically,
SMZL is characterised by a neoplastic inﬁltrate composed of an inner zone of small lymphocytes that replace the normal mantle zone,
and an outer zone of medium sized cells with clear cytoplasm in the location of the marginal zone where proliferation takes place [1,2].
The histological and immunophenotypic features of SMZL clearly separate it from nodal marginal zone lymphoma and extranodal mar-
ginal zone lymphoma of mucosa associated lymphoid tissue (MALT lymphoma). More recent studies also reveal distinct genetic changes
in SMZL, and interestingly many of these genetic changes affect the molecular pathways that govern the marginal zone B-cell develop-
ment. This review summarises the recent advances in genetic characterisation of SMZL and discuss their potential role in the lymphoma
pathogenesis.
2. Cell of origin of SMZL
The normal cell counterpart of SMZL is unclear [1], and the effort to deﬁne the differentiation stage of the B cells that give rise to SMZL
is hindered by a lack of understanding in the development of human splenic marginal zone B-cells. Nonetheless, SMZL shares the
immunophenotype (CD27+ IgM+ IgD+) of human splenic marginal zone B-cells [1,2,4]. There are also similarities in the pattern of somatic
hypermutation of the rearranged immunoglobulin heavy chain variable genes (IGHV) between SMZL and normal splenic marginal zone
B-cells albeit limited studies in the latter. Somatic hypermutations of the rearranged IGHV are seen in the vast majority (∼90%) of both
SMZL and normal splenic marginal zone B-cells [5–10]. The extent of these somatic mutations is also similar between SMZL and normal
splenic marginal zone B-cells, ranging from complete identity (100%) to the germline sequence, to minimally (97–99.9%) and signiﬁ-
cantly (<97%) mutated [5–10]. Finally, the characteristic mutation features of antigen selection are seen in a proportion of both SMZL and
splenic marginal zone B-cells [5–9]. These ﬁndings suggest that SMZL may have multiple cells of origins, deriving from heterogeneous
B-cells residing in the normal splenic marginal zone.
3. Marginal zone B-CELL development
The precise details on the generation of human splenic marginal zone B-cells, their migration to and retention in the splenic marginal
zone are unclear. In light of the presence of somatic mutations of the rearranged IG genes in the vast majority of human splenic marginal
zone B-cells, it is generally believed that these are IgMmemory B-cells that exit the germinal centre reaction prior to isotype switch [4,11,12].
The splenic marginal zone B-cells without somatically mutated IG genes may derive from the T-cell independent pathway [4,11–13]. There
are several molecular pathways or regulators that are known to play a critical role in marginal zone B-cell development (Fig. 1).
3.1. NOTCH2 signalling
The canonical NOTCH signalling is mediated by NOTCH ligand–receptor interaction between neighbouring cells. Upon binding by ligand
DLL1, the surface receptor NOTCH2 undergoes two successive proteolytic cleavages: ﬁrst to remove the extracellular domain by ADAM
family protease, then to release the NOTCH intracellular domain (NICD) by γ-secretase [14,15]. The liberated NICD translocates to the nucleus,
binds to the transcription factor RBPJ and transactivates its target genes [14,15]. During the transcriptional activation process, NICD is
NOTCH2  TLR   BAFFR CD40   BCR   
Marginal Zone B-cells 
(commitment, differentiation, migration and retention in splenic marginal zone)
Canonical NF-κB pathway Non-canonical NF-κB pathway Canonical NOTCH signalling
Fig. 1. Known surface receptors and their involved pathways critical for marginal zone B-cell development. A concerted action of these receptor signallings is thought to
govern the commitment and differentiation of marginal zone B-cells, their migration to and retention in the splenic marginal zone although the precise role of these re-
ceptor signallings is not totally clear.
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phosphorylated in its C-terminal PEST domain and targeted for proteasome-mediated degradation [14,15]. In mice, DLL1-mediated Notch2
signalling is critical for marginal zone B-cell differentiation and their retention in the splenic marginal zone, but appears to have little
impact on their cell proliferation and survival [14,16,17]. There is growing evidence indicating a similar role of DLL1-NOTCH2 signalling
in the development of human splenic marginal zone B-cells [18]. In line with this, expression of functional and membrane-bound DLL1
has also been recently demonstrated in innate lymphoid cells of the splenic marginal zone in human [12,19].
3.2. NF-κB signalling
Both canonical and non-canonical NF-κB pathways play a critical role in the development of marginal zone B-cells. The canonical NF-
κB pathway is activated by signalling from several surface receptors including BCR, TLR, IL-1R and TNFR, and is regulated by an auto-
negative feedback involving IκBα and TNFAIP3, particularly the latter. TNFAIP3 (also known as A20) can speciﬁcally inactivate several proteins
critical for the above signalling, such as RIP1/2, TRAF6, NEMO and TAK1, through its ubiquitin editing activities [20,21]. Similarly, the non-
canonical NF-κB pathway is activated by signalling from surface receptor including CD40, BAFFR (B-cell activating factor receptor) and
LTβR (lymphotoxin β receptor), and negatively regulated by TRAF3 [22].
In mice, the strength of BCR signalling regulates the fate decision between follicular and marginal zone B-cell development, with weak
BCR signalling, often triggered by auto-antigens, permitting Notch2 signalling and inducing marginal zone B-cell development [12,23].
This is probably also true for human splenic marginal zone B-cells in view of the characteristics of somatic mutations in their rearranged
IG genes and the functional properties of their BCR [12,23].
BAFFR signalling is critical for marginal zone B-cell development, and this appears to depend on the activation of the canonical NF-κB
pathway, rather than its ability to activate the non-canonical NF-κB pathway, which is important for B-cell survival [23,24]. CD40 signal-
ling, which activates the non-canonical NF-κB pathway and is critical for T-cell dependent B-cell responses, also plays a role in the development
of human marginal zone B-cells [13]. In line with these ﬁndings, the innate lymphoid cells of the splenic marginal zone in human express
functional surface BAFF and CD40L [12,19].
3.3. TLR signalling
Signalling from TLRs is another important pathway contributing to the development of human marginal zone B-cells. Patients with
defective TLR signalling due to deleterious mutations inMYD88, IRAK-4 and TIRAP show a speciﬁc reduction of marginal zone B-cells without
affecting the characteristics, such as somatic mutations and CDR3 sizes, of the rearranged IGH genes [25]. Several TLRs, particularly TLR10,
are expressed in normal splenic marginal zone B-cells [25]. It has been suggested that the TLR signalling may be more important for the
survival and maintenance rather than the differentiation of marginal zone B-cells [12,25]. The exact biological contribution of TLR sig-
nalling to the marginal zone B-cell development may depend very much on the concurrent cooperating signals particularly signalling from
BCR, and potentially also BAFFR [12,25].
3.4. KLF2 (Kruppel-like factor 2)
KLF2 is a recent addition to the list of regulators that are critical for the development of splenic marginal zone B-cells. KLF2 is a member
of the KLF family of transcription factors and has diverse functions in different cell lineages [26–29]. Its attention for an important role in
the development of marginal zone B-cells derives from conditional knockout studies in mice. Mice with Klf2 deﬁciency in B-cells show
an increase of marginal zone B-cells and splenic marginal zone hyperplasia [30–32]. Klf2 deﬁciency in B-cells appears to drive follicular
B-cells to gain a marginal zone like phenotype and migrate to the splenic marginal zone, but has little impact on their proliferation
[30–32]. Nonetheless, the pathways and molecular mechanisms by which KLF2 governs the marginal zone B-cell development remain to
be investigated.
3.5. Orchestrated signalling
The development of splenic marginal zone B-cells involves several distinct but integrated processes including commitment and
differentiation to a marginal zone B-cell phenotype, migration to the splenic marginal zone, and retention in this special anatomic niche.
Clearly, these various biological processes require different, most likely multiple and concerted signallings, and we are still at a primitive
stage of understanding these biological processes and their regulation. Nonetheless, the notion of concerted signalling is re-enforced by
the ﬁndings that human splenic innate lymphoid cells express surface BAFF, CD40L and DLL1 and provide contact-dependent
help to marginal zone B-cells by stimulation of the respective receptors in a cooperative manner [19]. Not surprisingly, these different
signalling pathways are the target of genetic changes, often occurring concurrently, in SMZL, further emphasising their cooperative
functions.
4. Antigenic drive in pathogenesis of SMZL
There is growing evidence that chronic antigenic drive may play an important role in the development of SMZL. This includes the ﬁnd-
ings of a strong association of HCV infection with SMZL and a biased usage of immunoglobulin genes by the lymphoma cells.
4.1. Role of HCV infection
HCV is a hepato- and lymphotropic virus and causes chronic infection with both hepatic and extrahepatic manifestations [33]. Among
extrahepatic manifestations, chronic HCV infection frequently leads to development of autoimmunity and lymphoproliferative disorders,
often featured by type-II mixed cryoglobulinemia [33]. Epidemiological studies and meta-analyses show a strong association among chronic
HCV infection, type-II mixed cryoglobulinemia, and several non-Hodgkin’s lymphomas including SMZL, particularly in geographical regions
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such as Italy, Japan, where HCV infection is endemic [33–38]. In the largest series of SMZL studied from Italy, evidence of HCV infection
was demonstrated in 25% of cases [34]. Importantly, antiviral therapy with interferon (with or without ribavirin) lead to complete or partial
lymphoma regression in a signiﬁcant proportion of cases with HCV-associated SMZL [39,40]. The lymphoma regression is most likely the
result of HCV clearance rather than an antiproliferative effect of interferon as a rapid regression of HCV-related SMZL is also seen follow-
ing an interferon-free, HCV NS3/NS4A inhibitor-based treatment [41]. Together, these ﬁndings suggest a causative role of HCV infection
in development of SMZL.
The regression of HCV-associated SMZL following antiviral therapy strongly indicates that the lymphoma cell survival critically depends
on the viral mediated antigenic stimulations. The stimuli and their molecular mechanisms underlying the viral mediated lymphomagenesis
are unclear. The potential factors may include: 1) binding of CD81 on B-cell surface by the HCV protein E2, which has been shown to ac-
tivate B-cells, particularly in the presence of BCR engagement [42]; 2) an increased production of cytokines and growth factors such as
BAFF and IL6 during HCV infection [43–45], which are known stimulators of B-cells; 4) Induction of TLR4 expression in B-cells by HCV
infection [46], which may potentially sensitise TLR signalling.
4.2. Biased usage of immunoglobulin genes
Several recent independent studies have investigated the immunoglobulin usage in large cohorts of SMZL, and these different studies
consistently show that three immunoglobulin heavy chain members namely IGHV1-2, IGHV4-34 and IGHV3-23 account for ∼45% of cases,
with IGHV1-2 usage being the most frequent (∼30%) [5–7,47]. Among the cases using IGHV1-2, the vast majority used allele *04 [5,6]. The
IGHV1-2*04 rearrangements in SMZL are characterised by minimal somatic mutations and longer complementarity determining region-3
(CDR3) sequence with common motifs, suggesting possible selection by superantigens [5,6]. In addition, the IGHV1-2*04 rearrangements
in SMZL were also associated with a biased usage of three light chain genes namely IGKV3-20, IGKV1-8 and IGLV2-14 [47]. Interestingly,
studies of recombinant antibodies from 5 SMZL with VH1-2*04 usage demonstrated that 4 of the 5 recombinant antibodies had similar
poly-reactivity to ubiquitous autoantigens [48]. In line with this, the majority of SMZL with IGHV1-2*04 usage showed clinical presenta-
tion of autoimmunity, although not associated with HCV infection [7]. Together these ﬁndings suggest that IGHV1-2 expressing BCR is
most likely auto-reactive and thus chronically activated by auto-antigens.
Apart from IGHV1-2*04, IGHV1-69 also appeared to be frequently used by SMZL with clinical presentation of autoimmunity, but in the
setting of HCV infection [7]. It is well established that patients with HCV associated mixed cryoglobulinemia have clonal marginal zone-
like B-cells expressing IGHV1-69 [49,50]. The clonal expansion of IGHV1-69 expressing B-cells is thought to be driven by HCV-E2 antigen
and cross linking of BCR by autoantibodies [51–53]. It is pertinent to speculate that such clonal IGHV1-69 expressing B-cells may undergo
malignant transformation and give rise to SMZL following acquisition of genetic abnormalities.
5. Genetic abnormalities in SMZL
Research to date has not identiﬁed any speciﬁc and recurrent chromosome translocation in SMZL although translocations involving
the CCND1, CCND3, BCL6,MUM1 or PAX5 loci were reported in isolated cases [54,55]. A number of studies by comparative genomic hybridisation
(CGH) have shown recurrent gains of 3q25-ter (22–32%), 6p (10%), 8q (8–20%), 12q13-21 (∼10%), 18 (12%), and losses of 6q (8–16%), 7q
(18–44%), 8p (∼15%) and 17p (8–14%) in SMZL [56–61]. Among these recurrent genomic gains and losses, 7q deletion is the most fre-
quent alteration in SMZL, and thus gained attention for further studies.
5.1. 7q deletion
By interphase ﬂuorescence in situ hybridisation (FISH), microsatellite LOH analysis and metaphase CGH investigation, several earlier
studies located the common region of 7q deletion in SMZL to an 11.4 Mb at 7q31.3–7q33 [62,63]. More recent studies by array CGHmapped
the minimal common region of 7q deletion to a ∼3 Mb region at 7q32.1–32.2 [60,61,64]. Screening of the 7q32 deletion by interphase
FISH showed the deletion in a third of SMZL and splenic B-cell lymphoma/leukaemia unclassiﬁable, but not or rarely in other lympho-
mas involving the spleen including chronic lymphocytic leukaemia and hairy cell leukaemia [60,61].
The genetic target(s) of 7q32 deletion in SMZL is unknown despite that several studies have attempted to identify the potential tumour
suppresser gene(s) targeted by the deletion. There is no evidence of homozygous deletion, nor recurrent breakpoints at 7q32 [60,61,64].
There are a number of coding genes and several non-coding microRNAs, which could be the potential targets of the deletion. The expres-
sion of many of the candidate genes was reduced in SMZL with 7q32 deletion in comparison with those without the deletion [64]. However,
sequencing of the candidate genes to date did not identify any recurrent pathogenic mutations [60,61,64]. It remains to be investigated
whether a haplodeﬁciency of one or more of these candidates genes may play a role in the pathogenesis of SMZL.
By array CGH, an additional common region (1.51 Mb) of deletion at 7q22.1 was also found in 49% of SMZL [65]. Interestingly, this
region was often not involved by the 7q deletion that enclosed 7q32. There are three coding genes at 7q22.1 and their candidacy as a
target of 7q22.1 deletion remains to be investigated.
5.2. NOTCH pathway mutation
Enhanced expression of NOTCH2 and its somatic mutation in SMZL were ﬁrst reported by Troen and colleagues [66,67], and their im-
portance in the lymphoma pathogenesis is reinforced by recent whole exome/genome sequencing (WES) studies [68–73].
NOTCH2 mutations are seen in 6.5–25% of SMZL, but not or rarely in other low grade B-cell lymphomas including chronic lymphocytic
leukaemia and hairy cell leukaemia [68,69]. Most NOTCH2 mutations are frameshift indels or nonsense mutations, and clustered up-
stream or within the C-terminal PEST domain that is critical for NOTCH2 proteasomal degradation (Figs. 2–4) [67–71,73]. These mutations
most likely eliminate or truncate the C-terminal PEST domain and thus potentially enhance the stability of the active NOTCH2 intracel-
lular domain, and its activities [67–71,73].
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Several mouse studies suggest that Notch2 signalling is critical for generation of marginal zone B-cells and their retention in the splenic
marginal zone [16,17,74,75], but appears to have little impact on cell proliferation and survival [16,17]. Thus, it is pertinent to speculate
that NOTCH2 activation by mutation may enhance the marginal zone B-cell differentiation, and their migration and localisation to the
splenic marginal zone, i.e. underscoring the characteristic phenotype of SMZL.
In addition to NOTCH2, WES studies also identiﬁed mutations in several other regulators of NOTCH signalling including NOTCH1, SPEN
and DTX1 in SMZL. The mutation frequencies in these additional NOTCH regulators were relatively low, but interestingly, mutations in
these genes appear to be largely mutually exclusive [68,69].
5.3. KLF2 mutation
Among somatic mutations identiﬁed in SMZL, KLF2 mutation is the most frequent, seen in 20–42% of cases [73,76,77]. KLF2 mutation
is also found in hairy cell leukaemia (10–16%), diffuse large B-cell lymphoma (0–11%), nodal marginal zone lymphoma (9%), MALT lym-
phoma (4–8%), and chronic lymphocytic leukaemia (0–3%) [73,76,77]. Themajority of KLF2mutations are frameshift indels, nonsensemutations,
or substitutions affecting the essential splice site, and localised toward the N-terminal activation domain (AD) and middle inhibitory domain
(ID). These mutations are predicted to result in a truncated protein product, with a high proportion of the mutants devoid of the nuclear
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localisation signal (Figs. 2–4). The remaining mutations are missense substitutions and clustered in the C-terminal zinc ﬁnger (ZF) 1, with
mutation hotspot at the conserved amino acids residues [73,76,77].
A pathogenic role of KLF2 inactivating mutations in SMZL is strongly supported by ﬁndings from studies of Klf2 knockout mice. Klf2
deﬁciency in B-cells appears to promote follicular B-cells to gain a marginal zone-like phenotype and migrate to the splenic marginal zone,
but has little impact on their proliferation [30–32]. Although the molecular mechanisms by which klf2 regulates B-cell homoeostasis and
traﬃcking are unclear, KLF2 is a member of the KLF family of transcription factors and has been shown to be a negative regulator of in-
ﬂammation and NF-κB activities [78–81]. In line with this, KLF2 mutations abolished its ability to suppress NF-κB activation by TLR, BCR,
BAFFR and TNFR signalling in vitro (Fig. 4) [73]. KLF2 inactivation by mutation may deregulate gene expression through the modulation
of NF-κB activities and other unknown mechanisms, thereby promoting B-cells homing to the splenic marginal zone.
5.4. NF-κB pathway mutation
Mutational analyses by candidate gene approach and WES have also uncovered somatic mutations in a number of NF-κB regulators in
SMZL. These include activating mutations in positive regulators such as CARD11 (∼7%), MYD88 (5–13%) and IKBKB (∼7%), and inactivating
mutations in negative regulators including TNFAIP3 (A20) (7–13%), BIRC3 (API2) (∼6%) and TRAF3 (∼5%) (Figs. 2–4) [68,72,73,82]. In general,
these mutations were largely mutually exclusive, and together seen in 30–40% of cases [68,73,82].
CARD11, MYD88 and IKBKB are positive regulators of the canonical NF-κB pathway and mutations in these regulators most likely cause
constitutive canonical NF-κB activities (Fig. 4) [83–85]. TNFAIP3 (A20) is a global negative regulator of the canonical NF-κB pathway and
can inactivate RIP1/2, TRAF6, NEMO, and TAK1, thus attenuating the signalling from several surface receptors including TNFR, TLR/IL1-R
and BCR (Fig. 4) [86]. TNFAIP3 (A20) inactivation by mutation most likely potentiates the signalling from these surface receptors, thereby
enhancing their mediated NF-κB activation. Similarly, BIRC3 and TRAF3 are negative regulators of the non-canonical NF-κB pathway and
their inactivation by mutation may argument the signalling by CD40 and BAFF receptor. Through the activation of the canonical and non-
canonical NF-κB pathways, these mutations may contribute to both the development and survival of marginal zone B-cells although their
precise role remains to be dissected.
5.5. Mutation in epigenetic regulation programme
Apart from mutations seen in the above molecular pathways important for marginal zone B-cell development, whole exome and tar-
geted sequencing has also identiﬁed mutations in several epigenetic regulators [68–71,77]. They include MLL2 (a histone methyltransferase),
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ARID1A (a member of the SWI/SNF adenosine triphosphate-dependent chromatin-remodelling complexes), EP300 (histone and non-
histone acetyltransferases), CBP (CREB-binding protein, a transcriptional coactivator/histone acetyl transferase/E3 ubiquitin ligase), SIN3A
(a core component of the SIN3-HDAC1/2 histone deacetylase complex), TBL1XR1 (an intrinsic component of the SMRT-N-CoR transcrip-
tion co-repressormachinery). Somaticmutations in these epigenetic regulators have also been reported in awide range of humanmalignancies,
and their role in lymphoma pathogenesis remain to be investigated.
5.6. TP53 mutations
TP53 mutations are seen in 10–15% of SMZL and most of these mutations are in the DNA binding or tetramerisation domains, thus
most likely inactivate TP53 function [73,77]. Like in other lymphomas, TP53 mutation in SMZL is likely a secondary genetic event. Among
the various genetic changes reported in SMZL, only TP53 inactivation has been consistently shown to be associated with poor prognosis
[61,73,77,87,88].
6. Oncogenic cooperation among genetic changes and antigenic stimulation
Among the diverse genetic changes identiﬁed in SMZL, only 7q deletion, KLF2 and NOTCH2 mutation, together with IGHV1-2 usage,
are frequent, with all other mutations occurred in <10% of cases. Several of these genetic changes show a signiﬁcant positive association,
suggesting a potential oncogenic cooperation in the pathogenesis of SMZL [73,76].
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Fig. 4. Somatic mutations in SMZL frequently target the regulators of NF-κB and NOTCH signalling that are critical for marginal zone B-cell development. The mutation
frequencies are indicated in bracket, with activating and inactivating changes in red and black text respectively. The molecular function of KLF2 is unknown, and its inac-
tivation by mutation may augment both canonical and non-canonical NF-κB activities, thus contributing to the SMZL development.
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The majority of SMZL with KLF2 mutation have both 7q32 deletion and IGHV1-2 rearrangement, and these cases also have additional
mutations in NOTCH2, or TNFAIP3 (A20), or TRAF3 (Fig. 3). The genes targeted by 7q32 deletion and their role in SMZL pathogenesis are
unclear [61,64]. Nevertheless, there is a potential cooperation between IGHV1-2 expressing BCR and KLF2/TNFAIP3 (A20) inactivation since
the activation of the canonical NF-κB pathway by the BCR signalling could be potentiated by inactivation of the negative regulators namely
KLF2 and TNFAIP3. Similarly, there is also a potential cooperation between KLF2 and TRAF3 inactivation as the activation of the non-
canonical NF-κB pathway by BAFF or CD40L could be augmented by concurrent inactivation of both KLF2 and TRAF3.
7. Conclusion remarks
Apart from the discovery of genetic changes in SMZL, the recent advances in identiﬁcation and characterisation of various surface re-
ceptors critical for marginal zone B-cell development and their biology havemade amajor contribution to our understanding of the lymphoma
pathogenesis. There are multiple receptor signallings and their concerted action governs the marginal zone B-cell differentiation, migra-
tion and retention in the splenic marginal zone. It is the components of these signalling pathways, which are targeted and deregulated
by genetic changes in SMZL. Interestingly, a high proportion of SMZL show concurrent genetic changes affecting multiple signalling path-
ways, thus potentially cooperating in their oncogenic properties. A functional characterisation of these genetic changes and their combined
oncogenic properties will help to illustrate the molecular pathogenesis of SMZL. In addition, a signiﬁcant proportion of SMZL, particular-
ly those negative for KLF2 mutations, show paucity of pathogenic mutations, and a further genetic characterisation of these cases may
continue to unravel novel genetic changes.
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